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Background: A large increase in nitric oxide fraction (FeNO) after radiotherapy (RT) for lung cancer may predict RT-
induced lung toxicity.
Methods: In this study, we assessed the relationships between FeNO variations and respiratory symptoms, CT scan
changes or dose volume histogram (DVH) parameters after RT. We measured FeNO before RT, 4, 5, 6, 10 weeks, 4
and 7.5 months after RT in 65 lung cancer patients.
Results: Eleven lung cancer patients (17%) complained of significant respiratory symptoms and 21 (31%) had
radiation pneumonitis images in >1/3 of the irradiated lung after RT. Thirteen patients (20%) showed increases in
FeNO >10 ppb. The sensitivity and specificity of a >10 ppb FeNO increase for the diagnosis of RT-associated
respiratory symptoms were 18% and 83%, respectively. There was no correlation between DVH parameters or CT
scan changes after RT and FeNO variations. Three patients (5%) showed intriguingly strong (2 or 3-fold, up to
55 ppb) and sustained increases in FeNO at 4 and 5 weeks, followed by significant respiratory symptoms and/or
radiation-pneumonitis images.
Conclusion: Serial FeNO measurements during RT had a low ability to identify lung cancer patients who developed
symptoms or images of radiation pneumonitis. However, three patients presented with a particular pattern which
deserves to be investigated.
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Measurement of exhaled nitric oxide fraction (FeNO) is
a non-invasive, well standardized, simple technique and
is regarded as a potential tool for screening and follow-
up of chest diseases. FeNO is increasingly used to moni-
tor airway inflammation in patients with asthma [1]. It
also may be useful in predicting steroid responsiveness
in chronic obstructive pulmonary disease [2], evaluating
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reproduction in any medium, provided the or[1], and identifying lung function deterioration in sclero-
derma [3]. While the need of biomarkers for early detec-
tion and follow-up of chest malignancies has been
recently highlighted [4,5], data on FeNO level at diagno-
sis or treatment-induced variations of FeNO are few.
FeNO has been found to be increased in patients with
Hodgkin disease, and to normalize after remission [6,7].
FeNO from lung cancer patients has also been found
higher than that from controls [8,9], and associated with
an up-regulation of inducible NO synthase (iNOS) activ-
ity in alveolar macrophages [8]. Serial measurements
have demonstrated that FeNO levels diminished after
chemotherapy [10] and/or radiotherapy (RT) [11].
Pulmonary toxicity remains a dose-limiting side-effect
of RT. It can impair the quality of life of patients, and beLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dosimetric data and patients’ characteristics have been
built to predict radiation-induced lung toxicity. However,
efficiency of these models is limited, and efforts to iden-
tify additional prognostic factors, including biomarkers,
are in progress [12,13]. Interestingly, in a series of 29
lung cancer patients, 5 demonstrated a three-fold in-
crease in FeNO during RT, and 3 of them subsequently
developed radiation pneumonitis requiring steroids [11].
In a study of oesophageal cancer, a 1.5-fold increase in
FeNO was observed in 4 patients with radiation pneu-
monitis symptoms, but not in the 24 asymptomatic
patients. Moreover, the interval to the occurrence of
peak symptoms was inversely related to the increase in
FeNO [14]. In another study by the same team, per-
formed in 50 patients with lung and oesophageal cancer,
all symptomatic patients had a >1.4-fold increase in
FeNO at the end of RT [15]. These studies suggest that
FeNO may be used for early detection of radiation-
induced lung injury. To extend these results, we assessed
the relationship between radiation-induced lung injury
and FeNO variations in 65 lung cancer patients.
This study was designed i) to describe the time-course
of FeNO till 7.5 months after 3D conformal RT ii) to as-
sess the relationship between FeNO variations and dose-
volume histogram analysis iii) to assess the relationship
between FeNO increases (using recommended criteria [1])
and respiratory symptoms or CT scan changes after RT
for lung cancer.
Methods
Patients
From October 2005 to February 2010, 65 patients with
histologically or cytologically confirmed unresectable
lung cancer accepted to participate and signed an
informed consent prior to registration in this observa-
tional study, which has been approved by the Institu-
tional Review Board (HUS n°3492). Lung cancer patients
with stage I-III, with or without pre-RT surgery or
chemotherapy were eligible. Patients were ineligible if
they were younger than 18 years, had history of prior RT
to the thorax, had an ECOG performance status >2, had
active systemic or pulmonary infection, asthma, atopy,
or synchronous malignancy within 2 years of entry.
Radiotherapy modalities
Patients were immobilized in a supine position with
arms above the head. Target volumes were delineated on
planning CT scan with 2.5 mm slices. The gross tumour
volume (GTV), clinical target volume (CTV), and plan-
ning target volume (PTV) were delineated according to
the definitions of the International Commission on Radi-
ation Units and Measurements [16], the GVT including
tumour and nodes visualised on CT and positronemission tomography (PET) -CT scan. CTV was defined
as the GTV with a 5-mm margin for the mediastinal
areas and a 5–8 mm margin for the primary tumour
according to the tumour histology. PTV (including set-
up margin and internal target volume) was obtained by a
2–10 mm 3D-expansion from CTV. In case of induction
chemotherapy, the post-chemotherapy volume of the
primary tumour was considered as the GTV of the pri-
mary tumour and the pathological lymph node areas
positive on the pre-treatment PET scan were included in
the GTV. After surgery, the CTV included the scar or
residual tumour, the pathological lymph node areas and
lymph node areas just above and below the pathological
one. Irradiation was applied with 2 to four 6–25 MV
photon beams from accelerators with multileaf linear
collimators. Portal imaging for set-up control was per-
formed daily. The irradiation dose was delivered with
conventional fractionation (2 Gy per fraction, 5 fractions
per week) up to 66 Gy. After lung resection, the dose
was 54 Gy for R0 resection and no nodal capsular rup-
ture. If resection was not R0, or nodal capsular rupture
was diagnosed, the dose was increased up to 66 Gy.
Dose Volume Histogram (DVH) parameters
Doses were calculated to account for tissue density het-
erogeneity. The lungs were automatically contoured, ex-
cluding the GTV. Mean lung dose (MLD, average dose
to the CT-defined total lung volume, excluding the
GTV), V5, V13, V20 and V30 (percentage of lung vol-
ume receiving at least 5, 13, 20 or 30 Gy) were calcu-
lated from the lung DVH.
Lung toxicity
Post-treatment cough or dyspnea grade 2 or higher
according to Common Terminology Criteria of Adverse
Events (CTCAE) v3.0, or significant increases in symp-
toms if patients presented with pre-existing symptoms,
were regarded as significant lung toxicity. These patients
were categorized as “symptomatic patients”.
CT Scan changes after radiotherapy
CT scan were performed within 4 weeks before, and
10 weeks, 4 and 7.5 months after the beginning of RT and
reviewed at the same time for each patient by the same
radiologist experienced in CT of the thorax. The system
used to score the extent of emphysema on the CT scans
was adapted from prior work by Goddard et al. [17] and
Bankier et al. [18]. Each CT section was assessed individu-
ally, and the right and left lungs were graded separately
according to the percentage area that demonstrated
changes suggestive of radiation pneumonitis. These
changes were ground-glass opacity, consolidation, fibrosis,
traction bronchiectasis, scarring, and volume loss.
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lung and in the left lung independently, as follow:
0 : none
<1 : minimal radiographic findings, volume <1 cm2
1 : changes with estimated proportion of lung volume
of <1/3
2 : changes with estimated proportion of lung volume
of >1/3 and <2/3
3 : changes with estimated proportion of lung volume
of >2/3
Scores obtained in the right and in the left lung were then
summed up to provide the grade for the whole lung. This
yielded maximum possible scores of 3 for the left side and
3 for the right side, for a maximum possible total score of
6. In this study, we regarded scores ≥2 as significant.
Exhaled NO measurement
Fractional exhaled NO was measured according to the
ATS–ERS guidelines [19]. In brief, FeNO was measured
online with a chemiluminescence analyser (NIOX; Aero-
crine, Solna, Sweden). The patients were instructed to
inhale to near-total lung capacity and to exhaleTable 1 Patients’ characteristics
Lung cancer patients (n = 65)
Males/Females 48/17
Age
(years, mean (SD))
61 (11)
Smoking history Current smoker 13
Ex smoker 49
Never smoker 3
Histology and stage NSCLC
squamous : 32
adenocarcinoma : 12
large cell : 4
unspecified : 4
Stage : I : 1
II : 4
III : 47
SCLC : 13
Stage : limited:
Treatment sequential chemo-RT : 21
concurrent chemo-RT : 40
no chemotherapy : 4
lung resection before RT : 14
DVH (mean (SD)) V5: 45% (15%)
V13: 31% (12%)
V20: 24% (10%)
V30: 17% (8%)
MLD: 12.9 Gy (4.6 Gy)
Baseline PFT Normal values : 15
Restrictive ventilatory defect : 13
Obstructive ventilatory defect : 37
(N)SCLC: (non) small cell lung cancer. DVH: dose volume histogram, MLD:
mean lung dose (Gy), PFT: pulmonary function test, V5, 13, 20, 300: percentage
of lung volume receiving at least 5, 13, 20 or 30 Gy (%).immediately at a constant flow rate of 50 ml/s during
10 sec. FeNO was calculated during the last 3 seconds of
the exhalation. Measurements were performed in tripli-
cate to obtain three acceptable FeNO measurements out
of a maximum of six attempts. Exhalations were
approved if they did not deviate more than 10%. FeNO
was expressed as the average of these three measure-
ments. With the NIOX system, a FeNO variation
>4 ppb is regarded as significant [20]. Some patients
accepted to perform FeNO measurements at various ex-
halation flow rates, i.e. 30, 50, 80 and 150 ml/s. Duration
of exhalation ranged from 12 sec for 30 ml/s to 8 s for
150 ml/s. For each flow rate we used the mean value of
two acceptable measurements. Elimination rates of NO
during each exhalation were plotted against exhalation
flow rates using a linear regression model. The slope of
this regression line represents the alveolar NO concen-
tration (Calv, ppb), and the intercept represents the
bronchial NO flux (JNO, pl/s) [21]. Alveolar and bron-
chial NO values were determined when the correlation
coefficient of the regression model was at least 0.9.
Exhaled NO measurements were performed within
2 weeks before RT, and 4, 5, 6, 10 weeks, 4 months and
7.5 months after the beginning of RT. Smoking and
treatment with inhaled or oral corticosteroids were
noted before each measurement.
Statistical analysis
Results are expressed as mean (standard deviation) or
proportions. Characteristics of the patients were com-
pared using t-test or chisquare test depending on the
variable being continuous or qualitative. Changes in
FeNO with time were evaluated using linear mixed
models with unstructured variance-covariances matrices.
Sensibility, specificity, positive and negative predictive
values of FeNO changes to predict respiratory symptoms
grade ≥2 or CT-scan images score ≥2 during the
7.5 months following RT were calculated with cut-off
values of 10 ppb, 4 ppb, and 2 fold-increase. According
to the American Thoracic Society criteria [1], in
patients, an increase in FeNO higher than 10 ppb for
FeNO values lower than 50 ppb from one visit to the
next is regarded as significant. Correlation at each time
between FeNO and DVH parameters or score of CT-
scan image was computed using Pearson or Spearman
correlation coefficient. The significance level was set at
alpha = 0.05. Computations were done with SAS 8.0
(PROX MIXED) and R 2.11.
Results
Patients’ characteristics, treatment and RT-induced
symptoms
Patients’ characteristics are reported in Table 1. All
patients received the planned RT dose. Disease
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patients within the study period. Eleven lung cancer
patients (17%) developed or increased significantly re-
spiratory symptoms, 4 during RT, 2 during the 3rd
month, 5 during the last month of the study, and were
diagnosed with radiation pneumonitis.
CT scan changes after radiotherapy
Results are reported in Table 2. Twenty-one (31%) of
lung cancer patients developed images score ≥2, at
10 weeks, 4 or 7.5 months.
Time course of FeNO and significant FeNO variations
Before RT, FeNO was in the range of normal values
(14.3 ppb (7.2)). A linear model fitted with the FeNO
time trend (slope: 0.15, p< 0.001). Mean FeNO
increased from 14.3 (7.2) ppb before RT to 18.2 (12.5)
ppb (+ 27% (8%)) at 7.5 months (Figure 1). Similarly, a
linear model fitted with the time trend of alveolar NO
(slope: 0.02, p< 0.01), which was higher at 7.5 months
than before RT (0.24 (0.16) to 0.34 (0.16) pl/s, + 42%
(6%)). Bronchial NO flux did not vary significantly after
RT. These serial alveolar and bronchial NO measure-
ments were obtained in 21 patients who accepted and
succeeded in performing multiple exhalations at various
flow rates.
Within the 10 first weeks period, 13 patients (20%)
showed at least one increase in FeNO >10 ppb (9
patients showed one, 2 patients showed 2, and 2 patients
showed 3 increases> 10 ppb).
Relationships between FeNO and, CT scan, dosimetric
parameters, or respiratory symptoms
There was no correlation between DVH parameters and
changes in FeNO (Figure 2). There was no correlation
between absolute values or variations in FeNO and the
score of CT scan changes after RT (Figure 3). However,
all DVH parameters correlated with the score of
radiation-induced CT-scan images at 4 months (with r
from 0.31 to 0.41, p< 0.05) and 7.5 months (with r from
0.45 to 0.54, p< 0.001).
In symptomatic patients, mean FeNO values were
13.7 ppb (10.5) at 4 weeks, 17.7 ppb (21.5) at 5 weeks
and 11.8 ppb (7.9) at 6 weeks. These values did not differ
from those observed in asymptomatic patients, whichTable 2 CT-scan image scores after radiotherapy
Score 10 weeks 4 months 7.5 months
n= 50 n= 53 n= 49
0- <1 36 (72%) 22 (42%) 18 (37%)
1-1.5 9 (18%) 17 (32%) 19 (39%)
2-2.5 3 (6%) 9 (17%) 9 (18%)
3 - >3 2 (4%) 5 (9%) 3 (6%)were 13.0 ppb (6.4) at 4 weeks, 12.9 ppb (7.4) at 5 weeks
and 14.0 (7.2) at 6 weeks.
The sensitivity of FeNO variations for the diagnosis of
RT-induced symptoms grade ≥2 was low (18%) for a
10 ppb increase (at least one increase within the 10 first
weeks). Specificity reached 83% (Table 3). The sensitivity
and specificity to detect symptoms and/or CT-san
images of score ≥2 were a little higher, reaching 22% and
87%, respectively. Using a >4 ppb increase (regarded as
the lowest clinical significant variation with our device [20])
as a threshold for symptoms detection, offered a sensitivity
of 36% and a specificity of 67%.
Three patients showed a particular pattern, with very
large and sustained rises of FeNO as early as 4 weeks:
two symptomatic patients showed a 2-fold (up to
+17 ppb) and 3-fold (up to +55 ppb) increase in FeNO,
respectively; one patient regarded as free of radiation-
induced symptoms (with pre-RT grade 1 cough, dyspnea,
and sputum, which increased only slightly within
4 months) presented a 3-fold increase in FeNO (up to
+27 ppb). These three patients had MLD of 13, 14, and
19 Gy, and presented with CT scan images score 1 at
10 weeks and 7.5 months (4 months : non available),
score 3 at 4 months, and score 5 at 4 months,Figure 1 Time course of FeNO (a), alveolar NO and bronchial
NO flux (b) in lung cancer patients (mean (SEM)). (a) FeNO
measured at 50 ml/s (FeNO50) in the whole group (solid line, 65
patients), and in the subgroup who accepted to perform
measurements at various exhalation flows to calculate alveolar NO
and bronchial NO flux (dotted line, 21 patients). See text for
comments.
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three patients were 27.2 ppb (8.0) at 4 weeks, 46.2 ppb
(26.5) at 5 weeks and 26.2 ppb (5.8) at 6 weeks. This was
significantly higher than the values observed in the other
62 patients (12.3 ppb (6.4) at 4 weeks (p< 0.05),
12.0 ppb (7.0) at 5 weeks (p< 0.01), and 12.9 ppb (6.8)
at 6 weeks (p< 0.05)). Taking into account these
patients, we evaluated the ability of FeNO to predict re-
spiratory symptoms after RT with a 2-fold increase
threshold (together with a significant increase of
>4 ppb). Sensitivity was 18%, specificity, 98%, positive
predictive value, 75% and negative predictive value, 85%.
Corticosteroids or smoking and FeNO
During the study period, 9 patients were treated with
inhaled corticosteroids (for chronic obstructive pulmon-
ary disease) and 13 with oral corticosteroids (11 for radi-
ation pneumonitis and 2 because of prophylactic brain
irradiation performed during the last two months). The
mean value of FeNO in treated patients was 12.8 (10.0)
ppb, lower than in non-treated patients (15.5 (10.6) ppb,Figure 2 Examples of relationships between dose volume
histogram (DVH) parameters and FeNO variations in lung
cancer patients at different time points. Diamonds: asymptomatic
patients. Circles: symptomatic patients. Black crosses: three patients
with particular pattern (both strong and sustained FeNO increase: cf
text for details).p< 0.05)). Thirteen patients continued smoking. The
mean FeNO value was 13.2 (11.4) ppb in smokers, lower
than in non-smokers (15.3 (8.8) ppb; p< 0.05). The in-
crease in FeNO observed in lung cancer at 4 and
7.5 months was not due to patients who stopped smok-
ing or had previous corticosteroids treatment. Among
the 4 patients who stopped smoking during the first
10 weeks, 1 showed a significant increase in FeNO two
weeks later, which therefore may have been a false posi-
tive induced by tobacco stop. Among the 11 patients
who developed respiratory symptoms without increase
in FeNO, 1 received corticosteroids between 6 and
10 weeks, which may have at least partially blunted NO
increase and lead to a false negative.
Discussion
The main findings of this study are the following. In
lung cancer, small increases in FeNO (4 ppb, 27% of
baseline value) and of alveolar NO were observed
7.5 months after the beginning of RT. Thirteen (20%)
lung cancer patients showed significant increases
(>10 ppb) in FeNO within the 10 weeks after RT begin-
ning. The specificity of FeNO increases> 10 ppb for pre-
dicting radiation-induced symptoms was high (83%), but
the sensitivity was very low (18%). Eventually, there was
no association between changes in FeNO and CT scan
images or with DVH parameters in the lung cancer
group.
The short-term impact of chemo and radiotherapy on
FeNO has been described in a few studies. Before treat-
ment, FeNO of lung cancer patients has been found to
be ~2.5 fold that of controls [8,9]. Eight days after carbo-
platin or cisplatin-based chemotherapy, FeNO decreased
by 3.8 ppb in 39 lung cancer patients and returned to
baseline values at days 15 [10]. After RT or combined
chemo-RT, in 29 patients, FeNO decreased by 35% atFigure 3 Example of relationship between score of radiation-
induced CT scan images and FeNO variations in lung cancer
patients. Diamonds: asymptomatic patients. Circles : symptomatic
patients. Black crosses: three patients with particular pattern (both
strong and sustained FeNO increase : cf text for details).
Table 3 Ability of a >10 ppb increase in FeNO [1] to predict respiratory symptoms (grade ≥2) and/or radiation-induced
CT-scan images (score ≥2) after radiotherapy in 65 patients with lung cancer
>10 ppb increase in FeNO Sensitivity Specificity Positive predictive value Negative predictive value
Respiratory symptoms 18% 83% 18% 83%
CT-scan images 24% 86% 45% 70%
Respiratory symptoms and/or CT-scan images 22% 87% 55% 61%
Eleven patients developed respiratory symptoms (17%). Thirteen (20%) showed at least one increase >10 ppb within 10 weeks.
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baseline FeNO was in the range of normal values, but
was measured after chemotherapy in almost all lung
cancer patients. Chemotherapy may have “normalized”
FeNO values. RT did not reduce FeNO in our patients.
It is well known that a tumour and its microenviron-
ment produce NO, which may promote tumour growth
mainly by stimulating angiogenesis. In lung cancer, the
main source of exhaled NO has been attributed to lung
macrophages [8,10]. Indeed, the magnitude of the indu-
cible nitric oxide synthase (iNOS) expression in alveolar
macrophages has been found to correlate with the level
of exhaled NO, and immunohistochemical studies indi-
cated that alveolar macrophages is likely the major cellu-
lar source of NO production [8]. In another study, the
decrease in FeNO observed at day 8 after chemotherapy
paralleled the decrease in monocytes in peripheral blood
[10]. The decrease in FeNO observed after treatment of
these chest malignancies is believed to be due to cell
death in the tumour and its microenvironment and/or
reduction of tumour-associated inflammation.
To our knowledge, this study is the first to provide
measurements of FeNO several months after RT for
chest malignancies. In lung cancer patients, FeNO
showed a small increase 4 and 7.5 months after theFigure 4 CT scan images observed 4 months after the
beginning of radiotherapy, in one of the three patients with a
strong and sustained increase in FeNO measured during
radiotherapy.beginning of radiotherapy, likely due to an increase in al-
veolar NO. The origin of this increase may be the recur-
rence or progression of the lung tumour. Tumour
recurrence or progression was diagnosed in 17 lung can-
cer patients in our series, but cannot be totally excluded
in other patients, since this diagnosis when based on
CT-scan imaging may be difficult after RT. Another ex-
planation may be the development of chemotherapy- or
radiation-induced lung damages. Indeed, if low-intermediate
chronic NO doses may promote tumour development/
progression [22], radiation therapy may produce high
levels of NO, which exert cytotoxic effects. These cyto-
toxic effects may have antitumor properties, but may also
induce damages in normal tissues. In mice, alveolar
macrophages produced NO after irradiation, and expres-
sion of iNOS in both alveolar macrophages and alveolar
epithelial cells are increased. Moreover, the progression of
radiation pneumonitis could be reduced with NOS inhibi-
tor treatment [23].
Three human studies assessed the predictive value of
FeNO for radiation pneumonitis symptoms. The first
one included 28 oesophagal cancer patients and found
that a 1.5-fold increase in FeNO had a 100% sensitivity
and 100% specificity [14]. In another study by the same
team, the ratio of FeNO at the end of RT to pre-RT was
calculated in 50 lung or oesophageal cancer patients. A
threshold of 1.4 perfectly separated symptomatic and
asymptomatic patients [15]. In the third study, 5 lung
cancer patients (17%) demonstrated a three-fold increase
in FeNO during RT. Three out of these 5 patients had
radiation pneumonitis requiring steroids [11]. In our
study, the specificity of a 10 ppb increase of FeNO for
detecting radiation pneumonitis symptoms in lung cancer
patients was quite good (83%), but the sensitivity was low
(18%). Using a lower threshold (increase >4 ppb, the low-
est significant increase with our device) did not improve
sufficiently the sensitivity of the test, which reached only
36%. Eventually, using a >2 fold increase (associated with
a minimal, >4 ppb increase) as cut point did not allow a
better detection of radiation-induced symptoms compared
to the 10 ppb cut-off value.
The low sensitivity of FeNO to detect radiation pneu-
monitis may be due to the development of respiratory
symptoms from other causes than radiation pneumon-
itis, such as exacerbation of underlying lung disease and
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curately dyspnea variations for patients with pre-existing
symptoms [24]. This is of real concern in case of popula-
tions characterized by a high proportion of patients with
pre-treatment pulmonary disease (75% of our patients had
impaired pre-treatment lung function) [24]. However,
interestingly, the sensitivity of FeNO in our study did not
increase dramatically (18% to 22%) when the diagnosis of
radiation lung injury was based on either symptoms and/
or CT scan images. Another reason for the low sensitivity
of FeNO may be the use of measurements performed at a
unique flow rate of 50 ml/s (FeNO50). At this flow rate,
NO, if not extremely elevated, is mainly of bronchial ori-
gin. In scleroderma, alveolar concentration of NO, but not
FeNO50, predicted degradation of lung function [3]. Given
that we showed alveolar NO varies with time after RT,
follow-up of the alveolar fraction of exhaled NO might be
more accurate than that of FeNO50 to detect radiation
pneumonitis, and deserves to be studied in larger popula-
tions. Eventually, the response of the lung to radiation
may vary from a patient to another, with activation of
various inflammatory pathways, and diverse patterns
of NO production. Interestingly, a sporadic form of
radiation pneumonitis has been described, character-
ized by a bilateral lymphocytic alveolitis, and similar
to hypersensitivity pneumonitis [25]. It would be of
interest to analyse the bronchoalveolar lavage from
patients with very strong and sustained increases in
FeNO, such as the three patients described in this
study, looking for lymphocytic alveolitis.
Our study was conducted in patients treated with RT,
whatever the lung cancer treatment prescribed prior to
or concomitant with RT. This heterogeneity of patients
may explain partly the low sensitivity of FeNO to predict
radiation-induced pneumonitis, since some chemother-
apy agents may have modulated the lung radiation-
induced toxicity and/or NO production. However, today,
lung cancer treatments frequently combine various
chemotherapy agents and RT modalities, and the inter-
est of FeNO measurements in the daily practice would
be limited if restricted to the follow-up of a particular
subgroup of patients. Moreover, numerous other factors,
such as corticosteroids, smoking, diet, may also have
confounding effects and add difficulty in interpreting
FeNO variations in these patients. In our study, tobacco
smoking and corticosteroid treatments were taken into
account and their potential effects could barely account
alone for the low sensitivity of FeNO. Eventually, false
positive are also a real issue. In our department, 2 out of
20 Hodgkin lymphoma patients without radiation pneu-
monitis showed unexplained, >10 ppb increases in
FeNO after RT (Enache I, unpublished data).
To conclude, in this study, a small proportion of lung
cancer patients developed symptoms of radiationpneumonitis, and serial FeNO measurements during RT
had a low ability to identify them. A larger proportion of
patients developed radiation pneumonitis images, but
FeNO variations did not correlate with the score of these
images. Three patients developed both large and sus-
tained increases in FeNO together with significant radi-
ation pneumonitis symptoms or images, which might
reflect a particular lung response to radiation.
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